Trial Profile
A Phase 3, Multicenter, Open-Label Extension Study to Evaluate the Long Term Efficacy and Safety of Mirikizumab in Patients With Moderately to Severely Active Ulcerative Colitis LUCENT 3
Status:
Recruiting
Phase of Trial:
Phase III
Latest Information Update: 19 Apr 2024
Price :
$35
*
At a glance
- Drugs Mirikizumab (Primary)
- Indications Ulcerative colitis
- Focus Registrational; Therapeutic Use
- Acronyms LUCENT 3
- Sponsors Eli Lilly and Company; Eli Lilly and Company (India) Pvt. Ltd; Eli Lilly Japan
- 12 Feb 2024 This trial has been completed in Germany, according to European Clinical Trials Database record.
- 12 Feb 2024 This trial has been completed in Germany, according to European Clinical Trials Database record.
- 10 Jan 2024 Planned number of patients changed from 960 to 1063.